Drug intelligence / Profile preview

64Cu-DOTA-TATE (Univ. of Pittsburgh)

Development stage
Preclinical
Lead developer
University of Pittsburgh
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals
01

Overview

64Cu-DOTA-TATE (Univ. of Pittsburgh): sourced facts only. name: "We explored targeting the SSTR2 receptor using Octreotate radiolabeled with copper-64 ( 64 Cu-DOTA-TATE) and found that specific uptake of 64 Cu-DOTA-TATE was highest in D341 cells with a mean and standard deviation of 39,272 +/- 826 counts as compared to 280 +/- 73 counts in D341 cells blocked with excess peptide." [DOI:10.1158/1535-7163.TARG-25-C089]; target: "We explored targeting the SSTR2 receptor using Octreotate radiolabeled with copper-64 ( 64 Cu-DOTA-TATE) and found that specific uptake of 64 Cu-DOTA-TATE was highest in D341 cells with a mean and standard deviation of 39,272 +/- 826 counts as compared to 280 +/- 73 counts in D341 cells blocked with excess peptide." [DOI:10.1158/1535-7163.TARG-25-C089]; developer: "University of Pittsburgh, Pittsburgh, PA." [DOI:10.1158/1535-7163.TARG-25-C089]; modality: "We hypothesize that targeted radiopharmaceutical therapy will result in higher uptake within the tumor while sparing the surrounding healthy brain." [DOI:10.1158/1535-7163.TARG-25-C089]; stage: "The mean standardized uptake value (SUV) following PET imaging of a mouse with an intracranial tumor was 0.31 in the tumor and 0.08 in the healthy brain at 1 hour, and 0.17 in the tumor and 0.08 in the healthy brain at 24 hours post-injection of 64 Cu-DOTA-TATE." [DOI:10.1158/1535-7163.TARG-25-C089]

02

Targets

SSTR2 (Somatostatin receptor type 2)

Beyond the preview

Go deeper on 64Cu-DOTA-TATE (Univ. of Pittsburgh).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 64Cu-DOTA-TATE (Univ. of Pittsburgh).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call